Zafgen receives $20.0M in Venture Round funding
Actavis, Forest Labs get second FTC request for merger info
Teva Pharmaceuticals will be releasing its generic version of Celebrex by year's end
Visit our sites for b2b sales and banking employees:
cafeb2bsales.com
cafebanking.com
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| West-Ward Pharmaceuticals | 2 | 7 | 250 % |
| Yakult | 4 | 11 | 175 % |
| Mylan | 3 | 7 | 133 % |
| A.P. Pharma | 28 | 63 | 125 % |
| EnVivo | 8 | 18 | 125 % |
| AP Pharma | 28 | 62 | 121 % |
| MEI Pharma | 1 | 2 | 100 % |
| Dragon Pharmaceutical | 2 | 4 | 100 % |
| Zydus Cadila | 1 | 2 | 100 % |
| UV Flu Technologies | 1 | 2 | 100 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Cadence Pharmaceuticals | 1 | 12 | 1100 % |
| Daxor | 1 | 8 | 700 % |
| Cardiome | 1 | 7 | 600 % |
| Biotest Pharmaceuticals | 2 | 13 | 550 % |
| Delcath | 1 | 6 | 500 % |
| Adamis Pharmaceuticals | 1 | 6 | 500 % |
| GenVec | 1 | 6 | 500 % |
| BSD Medical | 5 | 27 | 440 % |
| Cortex Pharmaceuticals | 5 | 25 | 400 % |
| ConBio | 2 | 10 | 400 % |